{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:34Z","timestamp":1792511614430,"version":"4.5.0"},"reference-count":162,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Integrins are transmembrane receptors that play a crucial role in cell adhesion and signaling by connecting the extracellular environment to the intracellular cytoskeleton. After binding with specific ligands in the extracellular matrix (ECM), integrins undergo conformational changes that transmit signals across the cell membrane. The integrin-mediated bidirectional signaling triggers various cellular responses, such as changes in cell shape, migration and proliferation. Irregular integrin expression and activity are closely linked to tumor initiation, angiogenesis, cell motility, invasion, and metastasis. Thus, understanding the intricate regulatory mechanism is essential for slowing cancer progression and preventing carcinogenesis. Among the four classes of integrins, the arginine-glycine-aspartic acid (RGD)-binding integrins stand out as the most crucial integrin receptor subfamily in cancer and its metastasis. Dysregulation of almost all RGD-binding integrins promotes ECM degradation in ovarian cancer, resulting in ovarian carcinoma progression and resistance to therapy. Preclinical studies have demonstrated that targeting these integrins with therapeutic antibodies and ligands, such as RGD-containing peptides and their derivatives, can enhance the precision of these therapeutic agents in treating ovarian cancer. Therefore, the development of novel therapeutic agents is essential for treating ovarian cancer. This review mainly discusses genes and their importance across different ovarian cancer subtypes, the involvement of RGD motif-containing ECM proteins in integrin-mediated signaling in ovarian carcinoma, ongoing, completed, partially completed, and unsuccessful clinical trials of therapeutic agents, as well as existing limitations and challenges, advancements made so far, potential strategies, and directions for future research in the field.<\/jats:p>\n                  <jats:p>Insight Box Integrin-mediated signaling regulates cell migration, proliferation and differentiation. Dysregulated integrin expression and activity promote tumor growth and dissemination. Thus, a proper understanding of this complex regulatory mechanism is essential to delay cancer progression and prevent carcinogenesis. Notably, integrins binding to RGD motifs play an important role in tumor initiation, evolution, and metastasis. Preclinical studies have demonstrated that therapeutic agents, such as antibodies and small molecules with RGD motifs, target RGD-binding integrins and disrupt their interactions with the ECM, thereby inhibiting ovarian cancer proliferation and migration. Altogether, this review highlights the potential of RGD-binding integrins in providing new insights into the progression and metastasis of ovarian cancer and how these integrins have been utilized to develop effective treatment plans.<\/jats:p>","DOI":"10.1093\/intbio\/zyaf003","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:26:56Z","timestamp":1738895216000},"source":"Crossref","is-referenced-by-count":9,"title":["Role of RGD-binding Integrins in ovarian cancer progression, metastasis and response to therapy"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-8661","authenticated-orcid":false,"given":"Vipin","family":"Ranga","sequence":"first","affiliation":[{"name":"DBT-North East Centre for Agricultural Biotechnology (DBT-NECAB), Assam Agricultural University , Agriculture University Road, Jorhat, Assam 785013 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-7391","authenticated-orcid":false,"given":"Tikam Chand","family":"Dakal","sequence":"additional","affiliation":[{"name":"Genome and Computational Biology Laboratory, Department of Biotechnology, Mohanlal Sukhadia University , University Road, Udaipur, Rajasthan 313001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-4600","authenticated-orcid":false,"given":"Pawan Kumar","family":"Maurya","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Central University of Haryana , Central University of Haryana Road, Mahendergarh, Haryana 123031 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Johnson","sequence":"additional","affiliation":[{"name":"Structural Bioinformatics Laboratory and InFLAMES Research Flagship Center, Biochemistry, Faculty of Science and Engineering, \u00c5bo Akademi University , Tykist\u00f6katu 6A, Turku 20520 ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8681-3840","authenticated-orcid":false,"given":"Narendra Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Banasthali Vidyapith , Vanasthali Road, Tonk, Rajasthan 304022 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[{"name":"Manipal Academy of Higher Education (MAHE) , Tiger Circle Road, Manipal, Karnataka 576104 ,","place":["India"]},{"name":"Institute of Bioinformatics , Discoverer Building, International Technology Park, Whitefield, Bangalore, Karnataka 560006 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2025020707265107500_ref1","volume-title":"Cancer Stat Facts: Common Cancer Sites","author":"National Cancer Institute, Surveillance, Epidemiology and End Results Program of the United States Government"},{"key":"2025020707265107500_ref2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"key":"2025020707265107500_ref3","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Review ovarian tumorigenesis a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"2025020707265107500_ref4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2025020707265107500_ref5","doi-asserted-by":"crossref","first-page":"x111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann Oncol"},{"key":"2025020707265107500_ref6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025020707265107500_ref7","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/934261","article-title":"Recent concepts of ovarian carcinogenesis: Type I and Type II","volume-title":"BioMed Research International","author":"Koshiyama"},{"key":"2025020707265107500_ref8","article-title":"What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors","volume-title":"Diagnostics: Multidisciplinary Digital Publishing Institute (MDPI)","author":"De Leo","year":"2021"},{"key":"2025020707265107500_ref9","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"2025020707265107500_ref10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/IGC.0000000000000677","article-title":"Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials","volume":"26","author":"Friedlander","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"2025020707265107500_ref11","article-title":"Review article advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis","volume":"7","author":"Li","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"2025020707265107500_ref12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat Commun"},{"key":"2025020707265107500_ref13","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025020707265107500_ref14","first-page":"1407","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume-title":"The American Journal of Surgical Pathology","author":"Przybycin"},{"key":"2025020707265107500_ref15","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ19-0283","article-title":"Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients","volume-title":"Endocrine Journal","author":"Nagasawa"},{"key":"2025020707265107500_ref16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project genie: powering precision medicine through an international consortium","volume":"7","author":"Sweeney","year":"2017","journal-title":"Cancer Discov"},{"key":"2025020707265107500_ref17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/his.13091","article-title":"Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology","volume":"70","author":"Ramalingam","year":"2017","journal-title":"Histopathology"},{"key":"2025020707265107500_ref18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025020707265107500_ref19","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025020707265107500_ref20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.omto.2023.02.006","article-title":"Targeting receptor tyrosine kinases in ovarian cancer: genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies","volume":"28","author":"Wei","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"2025020707265107500_ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-16-0492","article-title":"Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target","volume":"23","author":"Perales-Puchalt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.matbio.2004.08.001","article-title":"The emergence of integrins: a personal and historical perspective","volume":"23","author":"Hynes","year":"2004","journal-title":"Matrix Biol"},{"key":"2025020707265107500_ref23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/002215540205001010","article-title":"\u03b1v\u03b26 integrin-a marker for the malignant potential of epithelial ovarian cancer","volume":"50","author":"Ahmed","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"2025020707265107500_ref24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1523-1747.2001.01352.x","article-title":"avb6 integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes","volume":"116","author":"Thomas","year":"2001","journal-title":"J Invest Dermatol"},{"key":"2025020707265107500_ref25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"2025020707265107500_ref26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1091\/mbc.4.9.871","article-title":"The \u03b24 subunit cytoplasmic domain mediates the interaction of \u03b16\u03b24 integrin with the cytoskeleton of Hemidesmosomes","volume":"4","author":"Spinardi","year":"1993","journal-title":"Mol Biol Cell"},{"key":"2025020707265107500_ref27","doi-asserted-by":"crossref","first-page":"100966","DOI":"10.1016\/j.preteyeres.2021.100966","article-title":"Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration","volume":"85","author":"Van Hove","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"2025020707265107500_ref28","first-page":"13","article-title":"Focal adhesion a focal point in current cell biology and molecular medicine","volume":"1","author":"Wu","year":"2007","journal-title":"Cell Adhes"},{"key":"2025020707265107500_ref29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41556-018-0234-9","article-title":"Integrin activation by Talin, kindlin and mechanical forces","volume":"21","author":"Sun","year":"2019","journal-title":"Nat Cell Biol"},{"key":"2025020707265107500_ref30","first-page":"2719","article-title":"Comparing the expression of integrins \u03b1v\u03b23, \u03b1v\u03b25, \u03b1v\u03b26, \u03b1v\u03b28, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors","volume":"6","author":"Schittenhelm","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"2025020707265107500_ref31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/309030a0","article-title":"Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule","volume":"309","author":"Pierschbacher","year":"1984","journal-title":"Nature"},{"key":"2025020707265107500_ref32","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1073\/pnas.82.23.8057","article-title":"The effect of Arg-Gly-asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets","volume":"82","author":"Plow","year":"1985","journal-title":"Proc Nati Acad Sci USA"},{"key":"2025020707265107500_ref33","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.1073\/pnas.83.23.8819","article-title":"Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-asp cell-binding sequence","volume":"83","author":"Oldberg","year":"1986","journal-title":"Proc Nati Acad Sci USA"},{"key":"2025020707265107500_ref34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0092-8674(89)90945-8","article-title":"Two different Laminin domains mediate the differentiation of human endothelial cells into capillary-like structures In vitro","volume":"58","author":"Grant","year":"1989","journal-title":"Cell"},{"key":"2025020707265107500_ref35","doi-asserted-by":"crossref","first-page":"24756","DOI":"10.1016\/S0021-9258(17)31456-4","article-title":"The short amino acid sequence pro-his-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function","volume":"269","author":"Aota","year":"1994","journal-title":"J Biological Chem"},{"key":"2025020707265107500_ref36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.2821619","article-title":"New perspectives in cell adhesion: RGD and Integrins","volume":"238","author":"Ruoslahti","year":"1987","journal-title":"Science"},{"key":"2025020707265107500_ref37","first-page":"161","article-title":"Modulation of cancer-associated fibrotic stroma by an integrin \u03b1v\u03b23 targeting protein for pancreatic cancer treatment","volume":"11","author":"Turaga","year":"2021","journal-title":"CMGH"},{"key":"2025020707265107500_ref38","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/onc.2011.439","article-title":"CD49f and CD61 identify Her2\/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGF\u0392 signaling","volume":"31","author":"Lo","year":"2012","journal-title":"Oncogene"},{"key":"2025020707265107500_ref39","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101118","article-title":"The e-cadherin and n-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"key":"2025020707265107500_ref40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","article-title":"Tumor microenvironment in ovarian cancer peritoneal metastasis","volume":"23","author":"Mei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2025020707265107500_ref41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via \u03b15-integrin, which is a therapeutic target","volume":"68","author":"Sawada","year":"2008","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref42","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","article-title":"\u03b21-Integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids","volume":"159","author":"Casey","year":"2001","journal-title":"Am J Pathol"},{"key":"2025020707265107500_ref43","article-title":"Potential of integrin inhibitors for treating ovarian cancer: a literature review","volume":"9","author":"Kobayashi","year":"2017","journal-title":"Cancer"},{"key":"2025020707265107500_ref44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"\u03b21-Integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro","volume":"73","author":"Strobel","year":"1999","journal-title":"Gynecol Oncol"},{"key":"2025020707265107500_ref45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.0.CO;2-4","article-title":"Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the \u03b12\u03b21 integrin","volume":"67","author":"Moser","year":"1996","journal-title":"Int J Cancer"},{"key":"2025020707265107500_ref46","volume-title":"Clinical and Experimental Metastasis","author":"Dhaliwal"},{"key":"2025020707265107500_ref47","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","article-title":"Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis","volume":"69","author":"Slack-Davis","year":"2009","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref48","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.2353\/ajpath.2009.090028","article-title":"\u03b23-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer","volume":"175","author":"Kaur","year":"2009","journal-title":"Am J Pathol"},{"key":"2025020707265107500_ref49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat Med"},{"key":"2025020707265107500_ref50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin \u03b1v\u03b23 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"2025020707265107500_ref51","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1172\/JCI118227","article-title":"Antiintegrin \u03b1v\u03b23 blocks human breast cancer growth and angiogenesis in human skin","volume":"96","author":"Brooks","year":"1995","journal-title":"J Clin Investig"},{"key":"2025020707265107500_ref52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-007-9077-0","article-title":"Phase I and pharmacokinetic study of etaracizumab (Abegrin\u2122), a humanized monoclonal antibody against \u03b1v\u03b23 integrin receptor, in patients with advanced solid tumors","volume":"26","author":"Delbaldo","year":"2008","journal-title":"Invest New Drugs"},{"key":"2025020707265107500_ref53","first-page":"125","article-title":"A pilot trial of Vitaxin, a humanized anti-Vitronectin receptor (anti a v b 3 ) antibody in patients with metastatic cancer","volume":"16","author":"Posey","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"2025020707265107500_ref54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-\u03b1 v-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"O\u2019Day","year":"2011","journal-title":"Br J Cancer"},{"key":"2025020707265107500_ref55","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-06-2779","article-title":"Phase I evaluation of a fully human anti-\u03b1v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors","volume":"13","author":"Mullamitha","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/annonc\/mds505","article-title":"A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer","volume":"24","author":"Heidenreich","year":"2013","journal-title":"Ann Oncol"},{"key":"2025020707265107500_ref57","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","article-title":"Volociximab, a chimeric monoclonal antibody that specifically binds \u03b1 5\u03b2 1 integrin: a phase l, pharmacokinetic, and biological correlative study","volume":"14","author":"Ricart","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref58","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/onc.2010.532","article-title":"Ligand-independent activation of c-met by fibronectin and \u03b15 \u03921-integrin regulates ovarian cancer invasion and metastasis","volume":"30","author":"Mitra","year":"2011","journal-title":"Oncogene"},{"key":"2025020707265107500_ref59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","article-title":"A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer","volume":"121","author":"Bell-Mcguinn","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2025020707265107500_ref60","article-title":"RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field","volume":"13","author":"Ludwig","year":"2021","journal-title":"Cancer"},{"key":"2025020707265107500_ref61","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543784.17.8.1225","article-title":"Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme","volume":"17","author":"Reardon","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"2025020707265107500_ref62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-Angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Cancer Agents Med Chem"},{"key":"2025020707265107500_ref63","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ijc.25563","article-title":"Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study","volume":"128","author":"B\u00e4uerle","year":"2011","journal-title":"Int J Cancer"},{"key":"2025020707265107500_ref64","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41419-022-05472-7","article-title":"Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025020707265107500_ref65","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.863850","article-title":"Targeting Integrins for cancer therapy - disappointments and opportunities","volume":"10","author":"Bergonzini","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2025020707265107500_ref66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coph.2015.11.007","article-title":"Integrins and adhesion molecules as targets to treat inflammatory bowel disease","volume":"25","author":"Bravat\u00e0","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"2025020707265107500_ref67","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2018.00011","article-title":"Basement membrane defects in genetic kidney diseases","volume":"6","author":"Chew","year":"2018","journal-title":"Front Pediatr"},{"key":"2025020707265107500_ref68","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1111\/cas.14566","article-title":"Novel monoclonal antibody against integrin \u03b13 shows therapeutic potential for ovarian cancer","volume":"111","author":"Ke","year":"2020","journal-title":"Cancer Sci"},{"key":"2025020707265107500_ref69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136906","article-title":"Biphasic \u03b12\u03b21 integrin expression in breast cancer metastasis to bone","volume":"22","author":"Moritz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025020707265107500_ref70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1172\/JCI42328","article-title":"The \u03b12\u03b21 integrin is a metastasis suppressor in mouse models and human cancer","volume":"121","author":"Ramirez","year":"2011","journal-title":"J Clin Investig"},{"key":"2025020707265107500_ref71","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in cancer: cell-to-cell mediators of metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"key":"2025020707265107500_ref72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13402-019-00486-4","article-title":"The exosomal integrin \u03b15\u03b21\/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration","volume":"43","author":"Li","year":"2020","journal-title":"Cell Oncol"},{"key":"2025020707265107500_ref73","doi-asserted-by":"crossref","first-page":"e0242342","DOI":"10.1371\/journal.pone.0242342","article-title":"Circulating exosomes express \u03b14\u03b27 integrin and compete with CD4+ T cells for the binding to Vedolizumab","volume":"15","author":"Domenis","year":"2020","journal-title":"PloS One"},{"key":"2025020707265107500_ref74","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-04-2760","article-title":"Elevated Flk1 (vascular endothelial growth factor receptor 2) Signaling mediates enhanced angiogenesis in \u03b23-integrin-deficient mice","volume":"64","author":"Reynolds","year":"2004","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref75","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.98.4.1853","article-title":"Integrin activation controls metastasis in human breast cancer","volume":"98","author":"Felding-Habermann","year":"2001","journal-title":"PNAS"},{"key":"2025020707265107500_ref76","first-page":"2824","article-title":"Multiple roles for platelet GPIIb\/IIIa and \u03b1V\u03b23 Integrins in tumor growth, angiogenesis, and metastasis","volume":"62","author":"Trikha","year":"2002","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41389-020-00254-2","article-title":"The identification of nuclear \u03b1v\u03b23 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions","volume":"9","author":"Seraya-Bareket","year":"2020","journal-title":"Oncogenesis"},{"key":"2025020707265107500_ref78","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.cell.2019.05.006","article-title":"Single-cell multi-omic integration compares and contrasts features of brain cell identity","volume":"177","author":"Welch","year":"2019","journal-title":"Cell"},{"key":"2025020707265107500_ref79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025020707265107500_ref80","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1083\/jcb.200304105","article-title":"Differential \u03b1v integrin-mediated Ras-ERK Signaling during two pathways of angiogenesis","volume":"162","author":"Hood","year":"2003","journal-title":"J Cell Biol"},{"key":"2025020707265107500_ref81","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.0803728105","article-title":"Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis","volume":"105","author":"Murphy","year":"2008","journal-title":"PNAS"},{"key":"2025020707265107500_ref82","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58688","article-title":"Tumor stiffening reversion through collagen crosslinking inhibition improves t cell migration and anti-pd-1 treatment","volume":"10","author":"Nicolas-Boluda","year":"2021","journal-title":"Elife"},{"key":"2025020707265107500_ref83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2018.08.001","article-title":"Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype","volume":"435","author":"Chen","year":"2018","journal-title":"Cancer Lett"},{"key":"2025020707265107500_ref84","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-017-0659-y","article-title":"The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer"},{"key":"2025020707265107500_ref85","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1541-7786.MCR-16-0338","article-title":"Hypoxia selectively enhances integrin \u03b15\u03b21 receptor expression in breast cancer to promote metastasis","volume":"15","author":"Ju","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2025020707265107500_ref86","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1515\/BC.2003.120","article-title":"Ovarian cancer cell proliferation and motility is induced by engagement of integrin \u03b1v\u03b23\/vitronectin interaction","volume":"384","author":"Hapke","year":"2003","journal-title":"Biol Chem"},{"key":"2025020707265107500_ref87","article-title":"Integrated analysis of prognostic and immune associated integrin family in ovarian cancer","volume":"11","author":"Wu","year":"2020","journal-title":"Front Genet"},{"key":"2025020707265107500_ref88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New Engl J Med"},{"key":"2025020707265107500_ref89","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-010-9537-9","article-title":"A phase I study of continuous infusion cilengitide in patients with solid tumors","volume":"30","author":"O\u2019Donnell","year":"2012","journal-title":"Invest New Drugs"},{"key":"2025020707265107500_ref90","doi-asserted-by":"crossref","first-page":"112000","DOI":"10.1016\/j.biopha.2021.112000","article-title":"Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer","volume":"142","author":"Faria","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2025020707265107500_ref91","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1381406","article-title":"Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration","volume":"15","author":"Lee","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025020707265107500_ref92","first-page":"2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Pharmacology"},{"key":"2025020707265107500_ref93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcdb.2019.10.016","article-title":"A centralized communication network: recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors","volume":"101","author":"Leask","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"2025020707265107500_ref94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","article-title":"Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance","volume":"25","author":"Seguin","year":"2015","journal-title":"Trends Cell Biol"},{"key":"2025020707265107500_ref95","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12094-017-1724-0","article-title":"Inhibiting ERK\/Mnk\/eIF4E broadly sensitizes ovarian cancer response to chemotherapy","volume":"20","author":"Liu","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"2025020707265107500_ref96","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/jnci\/djt210","article-title":"Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer","volume":"105","author":"Kang","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2025020707265107500_ref97","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1038\/oncsis.2016.86","article-title":"Inhibition of the integrin\/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"2025020707265107500_ref98","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.addr.2013.09.017","article-title":"Nanotechnology approaches for personalized treatment of multidrug resistant cancers","volume":"65","author":"Minko","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2025020707265107500_ref99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025020707265107500_ref100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities key points","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2025020707265107500_ref101","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc2353","article-title":"Integrins in angiogenesis and lymphangiogenesis","volume":"8","author":"Avraamides","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2025020707265107500_ref102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425240903468696","article-title":"Integrin targeted drug and gene delivery","volume":"7","author":"Wang","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"key":"2025020707265107500_ref103","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-06-0100","article-title":"A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo","volume":"5","author":"Khalili","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2025020707265107500_ref104","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1158\/1078-0432.CCR-07-4530","article-title":"Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth","volume":"14","author":"Do\u00f1ate","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.bjc.6603171","article-title":"Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2), a beta integrin antagonist, in patients with solid tumours","volume":"94","author":"Cianfrocca","year":"2006","journal-title":"Br J Cancer"},{"key":"2025020707265107500_ref106","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ijc.20116","article-title":"CNTO 95, a fully human monoclonal antibody that inhibits \u03b1v integrins, has antitumor and antiangiogenic activity in vivo","volume":"110","author":"Trikha","year":"2004","journal-title":"Int J Cancer"},{"key":"2025020707265107500_ref107","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10585-007-9132-4","article-title":"CNTO 95, a fully human anti \u03b1v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells","volume":"25","author":"Chen","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"2025020707265107500_ref108","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1158\/1078-0432.CCR-04-2623","article-title":"Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-\u03b1v integrin monoclonal antibody, despite widespread tissue binding","volume":"11","author":"Martin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref109","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","article-title":"Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma","volume":"25","author":"Nabors","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025020707265107500_ref110","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4161\/cbt.8.23.10414","article-title":"The promise of antiangiogenic therapy for ovarian cancer","volume":"8","author":"Jazaeri","year":"2009","journal-title":"Cancer Biol Ther Landes Biosci"},{"key":"2025020707265107500_ref111","article-title":"Exploring the role of RGD-recognizing integrins in cancer","volume":"9","author":"Nieberler","year":"2017","journal-title":"Cancer"},{"key":"2025020707265107500_ref112","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5306\/wjco.v14.i7.230","article-title":"Stromal inflammation, fibrosis and cancer: an old intuition with promising potential","volume":"14","author":"Oey","year":"2023","journal-title":"World J Clin Oncol"},{"key":"2025020707265107500_ref113","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-18-2665","article-title":"Preclinical development and first-in-human imaging of the integrin \u03b1v\u03b26 with [18F]\u03b1v\u03b26-binding peptide in metastatic carcinoma","volume":"25","author":"Hausner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025020707265107500_ref114","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3892\/mmr.2015.4443","article-title":"Inhibition of integrin \u03b21 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK\/STAT1 signaling pathway","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"key":"2025020707265107500_ref115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1242\/dev.119.4.1093","article-title":"Embryonic mesodermal defects in \u03b15 integrin-deficient mice","volume":"119","author":"Yang","year":"1993","journal-title":"Development"},{"key":"2025020707265107500_ref116","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mehy.2014.11.018","article-title":"The specifical inhibition of the expression of integrin alpha5\/beta1 probably enhances the treatment effects and improves the prognosis of epithelial ovarian cancer","volume":"84","author":"Xie","year":"2015","journal-title":"Med Hypotheses"},{"key":"2025020707265107500_ref117","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"2025020707265107500_ref118","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J Control Release"},{"key":"2025020707265107500_ref119","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s12032-010-9621-1","article-title":"Integrin-targeted paclitaxel nanoliposomes for tumor therapy","volume":"28","author":"Meng","year":"2011","journal-title":"Med Oncol"},{"key":"2025020707265107500_ref120","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/acs.jmedchem.6b01711","article-title":"Emergence of small-molecule non-RGD-mimetic inhibitors for RGD Integrins","volume":"60","author":"Miller","year":"2017","journal-title":"J Med Chem"},{"key":"2025020707265107500_ref121","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.repbio.2018.07.005","article-title":"MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2","volume":"18","author":"Xiang","year":"2018","journal-title":"Reprod Biol"},{"key":"2025020707265107500_ref122","doi-asserted-by":"crossref","first-page":"113745","DOI":"10.1016\/j.biopha.2022.113745","article-title":"Integrin-mediated cancer progression as a specific target in clinical therapy","volume":"155","author":"Chen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025020707265107500_ref123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020242","article-title":"Personalized medicine: recent progress in cancer therapy","volume":"13","author":"Hoeben","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025020707265107500_ref124","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.seminoncol.2019.08.002","article-title":"Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications","volume":"46","author":"Rick","year":"2019","journal-title":"Semin Oncol"},{"key":"2025020707265107500_ref125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12885-019-5693-2","article-title":"Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma","volume":"19","author":"Burgos-Panadero","year":"2019","journal-title":"BMC Cancer"},{"key":"2025020707265107500_ref126","first-page":"3302","article-title":"Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells","volume-title":"Blood, The Journal of the American Society of Hematology","author":"Palumbo","year":"2000"},{"key":"2025020707265107500_ref127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.matbio.2014.03.001","article-title":"Role of osteopontin in the pathophysiology of cancer","volume":"37","author":"Shevde","year":"2014","journal-title":"Matrix Biol"},{"key":"2025020707265107500_ref128","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3892\/ol.2021.12831","article-title":"Tenascin-C promotes epithelial-to-mesenchymal transition and the mTOR signaling pathway in nasopharyngeal carcinoma","volume":"22","author":"Cheng","year":"2021","journal-title":"Oncol Lett"},{"key":"2025020707265107500_ref129","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.2174\/1381612820666140619123255","article-title":"SPARC in tumor pathophysiology and as a potential therapeutic target","volume":"20","author":"Feng","year":"2014","journal-title":"Curr Pharm Des"},{"key":"2025020707265107500_ref130","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3892\/ol.2020.11747","article-title":"Correlation of Fibulin-2 expression with proliferation, migration and invasion of breast cancer cells","volume":"20","author":"Zhang","year":"2020","journal-title":"Oncol Lett"},{"key":"2025020707265107500_ref131","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jcb.10702","article-title":"Modulation of prostate cancer growth in bone microenvironments","volume":"91","author":"Edlund","year":"2004","journal-title":"J Cell Biochem"},{"key":"2025020707265107500_ref132","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/0008-5472.CAN-15-0988","article-title":"Glioblastomas require integrin \u03b1v\u03b23\/PAK4 signaling to escape senescence","volume":"75","author":"Franovic","year":"2015","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref133","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-018-0694-6","article-title":"14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin \u03b1v\u03b23 and activating FAK\/PI3K\/AKT signaling","volume":"37","author":"Luo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2025020707265107500_ref134","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10120-014-0435-2","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 as prognostic, diagnostic, and therapeutic targets in gastric cancer","volume":"18","author":"B\u00f6ger","year":"2015","journal-title":"Gastric Cancer"},{"key":"2025020707265107500_ref135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10585-014-9675-0","article-title":"\u03b1v\u03b23, \u03b1v\u03b25 and \u03b1v\u03b26 integrins in brain metastases of lung cancer","volume":"31","author":"Berghoff","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"2025020707265107500_ref136","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/0008-5472.CAN-14-1990","article-title":"Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer","volume":"75","author":"Sharon","year":"2015","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref137","article-title":"OPN and \u03b1v\u03b23 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma","volume":"9","author":"Jin","year":"2014","journal-title":"PloS One"},{"key":"2025020707265107500_ref138","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.mpa.0000250129.64650.f6","article-title":"Determination of the ligand-binding specificities of the \u03b12\u03b21 and \u03b11\u03b21 Integrins in a novel 3-dimensional In vitro model of pancreatic cancer","volume":"34","author":"Grzesiak","year":"2007","journal-title":"Pancreas"},{"key":"2025020707265107500_ref139","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.stem.2019.11.016","article-title":"Zika virus targets glioblastoma stem cells through a SOX2-integrin \u03b1v\u03b25 Axis","volume":"26","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2025020707265107500_ref140","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1038\/onc.2010.107","article-title":"Ovarian cancer ascites protects from TRAIL-induced cell death through \u03b1v\u03925 integrin-mediated focal adhesion kinase and Akt activation","volume":"29","author":"Lane","year":"2010","journal-title":"Oncogene"},{"key":"2025020707265107500_ref141","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ejca.2004.12.031","article-title":"\u03b1v\u03b25-integrins mediate early steps of metastasis formation","volume":"41","author":"Enns","year":"2005","journal-title":"Eur J Cancer"},{"key":"2025020707265107500_ref142","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1128\/MCB.02404-06","article-title":"Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin \u03b26","volume":"27","author":"Azare","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2025020707265107500_ref143","first-page":"2811","article-title":"Study on the effect of integrin \u03b1V\u03b26 on proliferation and apoptosis of cervical cancer cells","volume":"21","author":"Liang","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025020707265107500_ref144","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","article-title":"Antibody-mediated blockade of integrin \u03b1v\u03b26 inhibits tumor progression in vivo by a transforming growth factor-\u03b2-regulated mechanism","volume":"68","author":"AaVKA","year":"2008","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tranon.2018.02.013","article-title":"Integrin \u03b1v\u03b26 promotes lung cancer proliferation and metastasis through upregulation of IL-8\u2013mediated MAPK\/ERK Signaling","volume":"11","author":"Yan","year":"2018","journal-title":"Transl Oncol"},{"key":"2025020707265107500_ref146","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3701-4-53","article-title":"Integrin \u03b1v\u03b26 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer","volume":"4","author":"Peng","year":"2014","journal-title":"Cell Biosci"},{"key":"2025020707265107500_ref147","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju169","article-title":"Therapeutic targeting of integrin \u03b1v\u03b26 in breast cancer","volume":"106","author":"Moore","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025020707265107500_ref148","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1038\/onc.2017.248","article-title":"Glioblastoma stem cells exploit the \u03b1v\u03b28 integrin-TGF\u03b21 signaling axis to drive tumor initiation and progression","volume":"36","author":"Guerrero","year":"2017","journal-title":"Oncogene"},{"key":"2025020707265107500_ref149","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26352-2","article-title":"Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation","volume":"12","author":"Lain\u00e9","year":"2021","journal-title":"Nat Commun"},{"key":"2025020707265107500_ref150","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.1158\/0008-5472.CAN-08-3350","article-title":"Confounding effects in \u201ca six-gene signature predicting breast cancer lung metastasis\u201d","volume":"69","author":"Culhane","year":"2009","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref151","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.21873\/anticanres.16680","article-title":"Interaction of integrin \u03b1v\u03b28 with type I collagen promotes squamous cell carcinoma cell motility via RAC1 activation","volume":"43","author":"Ishida","year":"2023","journal-title":"Anticancer Res"},{"key":"2025020707265107500_ref152","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.7150\/jca.43826","article-title":"Integrin \u03b1v\u03b28 serves as a novel marker of poor prognosis in colon carcinoma and regulates cell invasiveness through the activation of TGF-\u03b21","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cancer"},{"key":"2025020707265107500_ref153","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1165\/rcmb.2009-0375OC","article-title":"\u03b15\u03b21-integrin expression is essential for tumor progression in experimental lung cancer","volume":"43","author":"Roman","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025020707265107500_ref154","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.surg.2004.04.006","article-title":"Inhibition of \u03b15 integrin decreases PI3K activation and cell adhesion of human colon cancers","volume":"136","author":"Murillo","year":"2004","journal-title":"Surgery"},{"key":"2025020707265107500_ref155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1242\/jcs.071985","article-title":"Integrin \u03b15\u03b21 facilitates cancer cell invasion through enhanced contractile forces","volume":"124","author":"Mierke","year":"2011","journal-title":"J Cell Sci"},{"key":"2025020707265107500_ref156","article-title":"Targeting integrin \u03b15\u03b21 in urological tumors: opportunities and challenges","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"2025020707265107500_ref157","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1097-0045(19980515)35:3<185::AID-PROS4>3.0.CO;2-G","article-title":"Role of \u03b1IIb\u03b23 integrin in prostate cancer metastasis","volume":"35","author":"Trikha","year":"1998","journal-title":"Prostate"},{"key":"2025020707265107500_ref158","first-page":"2522","article-title":"The high affinity \u03b1IIb\u03b23 integrin is involved in invasion of human melanoma cells","volume":"57","author":"Trikha","year":"1997","journal-title":"Cancer Res"},{"key":"2025020707265107500_ref159","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.str.2017.09.007","article-title":"The therapeutic antibody LM609 selectively inhibits ligand binding to human \u03b1V\u03b23 integrin via steric hindrance","volume":"25","author":"Borst","year":"2017","journal-title":"Structure"},{"key":"2025020707265107500_ref160","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A randomized phase 2 study of Etaracizumab, a monoclonal antibody against integrin avb3, Dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"2025020707265107500_ref161","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/annonc\/mds281","article-title":"Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer","volume":"24","author":"Besse","year":"2013","journal-title":"Ann Oncol"},{"key":"2025020707265107500_ref162","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/annonc\/mdv219","article-title":"Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)","volume":"26","author":"Vansteenkiste","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyaf003\/61780320\/zyaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyaf003\/61780320\/zyaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:27:40Z","timestamp":1738895260000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ib\/article\/doi\/10.1093\/intbio\/zyaf003\/8003938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":162,"URL":"https:\/\/doi.org\/10.1093\/intbio\/zyaf003","relation":{},"ISSN":["1757-9708"],"issn-type":[{"value":"1757-9708","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"zyaf003"}}